Secures Three U.S. Sites for NASARIX Trial

Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced it has signed agreements with two additional U.S. clinical sites. This brings the total to three major contracted sites for its upcoming NASARIX (PL-14) clinical study.

These three sites represent the largest and most strategically important centers in the Company’s planned multi-center clinical trial and are expected to contribute the highest rates of patient enrollment. The study will evaluate the safety, tolerability, and efficacy of the NASARIX Allergy Blocker in patients with seasonal allergic rhinitis.

This progress follows the Company’s recent announcement of its first U.S. clinical site, which the Company believes shows strong execution of its clinical plan.

“We are very encouraged by the rapid expansion of our clinical site network, particularly with the addition of two highly experienced and high-enrollment centers,” said Tomer Izraeli, CEO of Polyrizon. “We believe that securing the three leading sites early positions us strongly for efficient patient recruitment and timely study execution as we prepare to initiate our multi-center clinical trial.”

The study, titled “Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis,” is designed as a multi-center trial in the United States, with up to five clinical sites expected to participate.

The NASARIX investigational product is an intranasal hydrogel formulation intended to create a protective physical barrier in the nasal cavity to block airborne allergens at the point of entry, potentially offering a non-pharmacological approach to allergy prevention.

The trial will be conducted in accordance with international Good Clinical Practice (GCP) standards and applicable regulatory requirements, supporting the Company’s broader regulatory strategy.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain ^TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.

Schreibe Deinen Kommentar